Gain: Positive Results in Exploratory Endpoint in Phase 1b Clinical Study in Parkinson's

 Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint

The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson’s disease (PD)

KOL event planned for early January to discuss the results; registration information herein

Gain Therapeutics will host a webinar “Understanding GCase Substrates in Parkinson’s Disease: Perspectives on Biomarkers and Disease Modification, Contextualizing emerging biomarker data from the Phase 1b clinical study of GT-02287”, featuring key opinion leaders Roy Alcalay, M.D., M.Sc., and Peter Lansbury, Ph.D., on Tuesday, January 6, 2026 at 10:00 a.m. ET to discuss the results announced today and host a question-and-answer session. Additional details about the event will be issued closer to the event in a separate press release. To register, please click here.

https://finviz.com/news/257088/gain-therapeutics-announces-positive-results-in-key-exploratory-endpoint-from-its-phase-1b-clinical-study-of-gt-02287-in-people-with-parkinsons-disease